Why I bought Swiss Glascoat (HLE Glascoat) and Why it Multiplied 200 Times !!
How to find a good Stock Advisor?
March 15, 2019
My Portfolio CAGR (XIRR) as on 01.11.2024 is 112%
November 5, 2024
Swiss Glascoat — Now HLE Glascoat Ltd
On 3 April 2014 I publicly wrote: “Buy Swiss Glasscoat at ₹38.60… I hold the stock.” Today, as HLE Glascoat and adjusted for its 5:1 split, that call is worth roughly 55 times the entry price — and at its 2021 peak, ₹5 lakh invested had become nearly ₹10 crore, a ~200-fold ascent. Here is exactly why I bought a niche engineering company most investors had never heard of.
A hidden monopoly-like business
Glascoat makes glass-lined reactors and equipment — the specialised vessels in which pharmaceutical and specialty-chemical companies run corrosive reactions — plus filtration and drying systems. It is not a household name, but it is India’s number-two player in a market with essentially two serious suppliers. When you sell mission-critical equipment in a near-duopoly to booming pharma and chemical customers, you have real pricing power. That is exactly the kind of quiet, defensible business I look for.
The fundamental strengths that made me buy
- Duopoly economics. In glass-lined equipment there are effectively only two credible suppliers in India — a structural moat that protects margins and returns.
- Two engines, not one. A glass-lined equipment division and a filtration-and-drying division, both selling into the same high-growth pharma and specialty-chemical customers.
- A global acquisition. The 2021 purchase of Germany’s Thaletec added international technology, a global footprint and blue-chip European clients.
- High promoter conviction. Promoters hold ~66% — management’s money sits right alongside mine.
- Riding pharma & China+1. Every wave of pharma and agrochemical capacity expansion, and every China+1 sourcing shift, drives fresh demand for its reactors.
- Real, growing profits. FY26 revenue of ~₹1,353 crore — a specialist that has scaled into a substantial business.
Why the peak was 200× and the entry still looks cheap
From my ₹38 entry the stock is about 55× today; at its 2021 high the compounding was extraordinary — ₹5 lakh had become ₹10 crore, roughly 200 times. Either way, the lesson is the same. A specialised, near-monopoly supplier to a structurally growing industry gets re-rated relentlessly as its customers expand. I did not need to predict the exact peak; I only needed to own the right business and let the industry’s growth do the rest.
Don’t take my word for it — it’s on the public record
The proof is above: my dated public buy call from 3 April 2014, at ₹38.60, with “I hold the stock” in my own words. I put my name and my capital behind the idea before it was obvious — which is the only time it is still cheap.
“The most powerful businesses are often the ones nobody can see — the quiet suppliers that every growing industry cannot do without.”
The lesson for you
Glascoat taught me to hunt for the ‘picks-and-shovels’ — the unglamorous, mission-critical suppliers hiding behind a booming sector. You don’t have to bet on which pharma company wins; you just have to own the company that sells all of them the equipment they cannot operate without.
Want to catch stocks like these before they move?
Explore how you can work with me — the same value-investing framework that found these winners, now applied for you.
Disclaimer: This article is a personal account of my own past investment decision, shared for educational purposes only. It is not a recommendation to buy or sell this or any stock at current prices. All return figures are calculated to recent market prices and adjusted for stock splits and bonuses; past performance is not a guarantee of future returns. Equity investments are subject to market risks. Please do your own research or consult your financial adviser before investing.
